Compulsory licensing sets off a wave of price cuts in cancer drugs Livemint Some of the key cancer drugs under patent protection in India—erlotinib (lung cancer), sunitinib (kidney cancer), sorafenib (liver and kidney cancer), trastuzumab (breast cancer) and rituximab (blood and lymphatic cancer)—are neither subjected to ... |
